Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer
European Journal of Clinical Pharmacology · 2026-04 · 82 (4)
DOI: 10.1007/s00228-026-04037-3 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 30.03.2026. Verfasst von Kadri Altundag. Beteiligte Einrichtung: MKA Breast Cancer Clinic, Tepe Prime, Cankaya, Ankara, 06800, Turkey. altundag66@yahoo.com. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- MKA Breast Cancer Clinic, Tepe Prime, Cankaya, Ankara, 06800, Turkey. altundag66@yahoo.com.
Zitieren
APA
Altundag, K. (2026). Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer. European Journal of Clinical Pharmacology, 82(4). https://doi.org/10.1007/s00228-026-04037-3
Vancouver
Altundag K. Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer. European Journal of Clinical Pharmacology. 2026;82(4). doi:10.1007/s00228-026-04037-3
BibTeX
@article{Altundag2026,
author = {Altundag, Kadri},
title = {Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
volume = {82},
number = {4},
doi = {10.1007/s00228-026-04037-3}
}
EUVIMED